IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect IRL-201104’s likelihood of approval (LoA) and phase transition for Eosinophilic Esophagitis took place on 11 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IRL-201104 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
IRL-201104 is under development for the treatment of asthma, allergies, eosinophilic esophagitis, grass pollen allergy, seasonal allergic rhinitis, coronavirus disease 2019 (COVID-19), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome. The drug candidate is a peptide derived from mycobacterium tuberculosis chaperonin 60.1. It is administered through intravenous and subcutaneous routes.
It was also under development for dermatological indications.
Revolo Biotherapeutics overview
Revolo Biotherapeutics is developing first-in-class disease resetting therapeutics for inflammatory and immunological diseases. The company’s pipeline products including PIN201104 (1104) and IRL201805 (1805) are drug compounds derived from endogenous immunoregulatory proteins (mTB chaperonin and BiP) for the treatment of asthma and rheumatoid arthritis. It is developing novel immunomodulatory platforms that reset the immune system advancing the control and management of chronic inflammatory diseases facilitating disease modification and remission. Revolo Biotherapeutics is headquartered in Stevenage, Hertfordshire, the UK.
Quick View IRL-201104 LOA Data
|Highest Development Stage|